<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870037</url>
  </required_header>
  <id_info>
    <org_study_id>ION 03-OAB</org_study_id>
    <nct_id>NCT01870037</nct_id>
  </id_info>
  <brief_title>Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer</brief_title>
  <acronym>OAB</acronym>
  <official_title>Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Urovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ion Channel Innovations</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Urovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of a single treatment of
      hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections.
      Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in
      females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration
      will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 double-blind, placebo-controlled study assessing the safety and activity of
      2 escalating doses of hMaxi-K gene transfer by direct injection into the bladder wall in
      female participants with OAB/DO.

      The safety parameters to be monitored include: adverse events, clinical laboratory tests,
      electrocardiograms, and physical examinations.

      The secondary objective is to evaluate the efficacy of multiple intramuscular injections of
      hMaxi-K compared to the control group. Efficacy parameters that will be evaluated are: number
      of micturitions per 24 hours, volume per micturition, incontinence episodes, pad weight
      measurement of accidental bladder leaks, uninhibited contractions during cystoscopy and other
      cystoscopic evaluations, and general and bladder-specific quality of life assessments (Kings
      Health Questionnaire, SF-12 Health Survey, and International Consultation on Incontinence
      Questionnaire [ICIQ-SF]).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">February 17, 2018</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>sequential, dose escalation</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant clinical laboratory test value during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant clinical laboratory test value during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant electrocardiogram finding during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant electrocardiogram finding during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant physical examination finding during the Treatment Period</measure>
    <time_frame>6 months (24 weeks) per participant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with any clinically significant physical examination finding during the Safety Follow-up Period</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the number of micturitions per day</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the volume of micturitions</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in incontinence episodes</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in pad weight</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in uninhibited contractions during cystoscopy</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the participant rating of the Kings Health Questionnaire (KHQ) score</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the International Consultation on Incontinence Questionnaire-Short Form score</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Short Form-12 (SF-12) score</measure>
    <time_frame>Baseline; 6 months (24 weeks) per participant</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Placebo (PBS-20% sucrose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hMaxi-K 16000 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hMaxi-K 24000 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PBS-20% sucrose)</intervention_name>
    <arm_group_label>Placebo (PBS-20% sucrose)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMaxi-K</intervention_name>
    <description>Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)</description>
    <arm_group_label>hMaxi-K 16000 µg</arm_group_label>
    <arm_group_label>hMaxi-K 24000 µg</arm_group_label>
    <other_name>URO-902</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy women of ≥18 years of age and non-childbearing potential

          2. Symptoms of overactive bladder for ≥6 months including at least one of the following:

               1. Frequent micturition ≥8 times per 24 hours

               2. Urinary urgency or nocturia

               3. Urge urinary incontinence five or more incontinence episodes per week

          3. Detrusor overactivity with ≥1 uncontrolled phasic contraction(s) of the detrusor of at
             least 5 centimeters/H20 pressure documented on cystometry at Screening Visit 1A

          4. Residual urine volume of ≤200 milliliters (ml)

          5. Non-response or poor tolerance to previous treatment for symptoms of OAB/urinary
             incontinence and do not wish to continue these treatments

          6. Have screening laboratory values and electrocardiogram that are within the normal
             range

          7. Able to understand study requirements (i.e., literate in English), give written
             informed consent, and comply with all study procedures and requirements.

        Exclusion Criteria:

          -  A woman with a positive serum (HCG) pregnancy test or who is lactating

          -  History of three or more culture-documented recurrent urinary tract infections per
             year

          -  Current history or previous diagnosis of painful bladder syndrome (interstitial
             cystitis) with pain in the region of the pelvis, perineum, or lower abdomen relieved
             by voiding

          -  Current history of neurological bladder dysfunction

          -  A life expectancy of less than 12 months

          -  Current history of Grade 2 or greater cystocele

          -  An indwelling urethral catheter or need for clean intermittent self-catheterization

          -  Recent heart attack

          -  Uncontrolled diabetes

          -  Latex allergy

          -  Stress urinary incontinence as determined by observation of the participant coughing
             while standing with a full bladder and/or response of 2 or 3 on the following Stress
             Urinary Incontinence question: Do you experience leakage when laughing, coughing,
             lifting heavy objects or other types of discreet, moderately intense activities?
             0=NONE: No leakage. 1=MILD: Minimal leakage on rare occasions during these types of
             activities; easily tolerated; do not use pads for this. 2=MODERATE: Enough leakage
             that it requires occasional use of pads and may interfere with usual activity and
             tasks. 3=SEVERE: Extreme leakage and discomfort that stops all activity and tasks and
             requires the use of pads on all occasions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>OAB</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>individual participant data will not be shared</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01870037/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01870037/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT01870037/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

